Sun Pharma launches novel drug 'Palbociclib' for breast cancer

11 Jan 2023 , 11:18 AM

Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has launched Palbociclib, a novel anti-cancer drug, in India for patients with advanced breast cancer, the country’s most common cancer among women. The drug will be marketed under the brand names PALENOTM (Palbociclib) 75 mg, 100 mg, and 125 mg.

Palbociclib is approved for use in combination with hormonal therapies for patients with hormone receptor-positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer by the USFDA, EMA, and CDSCO.

Sun Pharma’s CEO – of India Business, Kirti Ganorkar, stated ‘We are introducing Palbociclib at a low cost to improve patient access. PALENOTM will be used to treat several advanced breast cancer patients in India. We are introducing a novel patient assistance program for the first time, which will improve patient compliance and accessibility.’ 

Breast cancer is the most common type of cancer in India, with approximately 0.21 million new female patients diagnosed each year.

At around 11.13 AM, Sun Pharma was trading at Rs1,023.10 apiece, up by 1.30% against the previous close of Rs1,011.85 on NSE. The counter touched an intraday high and low of Rs1,026.95 and Rs1,008.35 respectively.

For feedback and suggestions, write to us at [e-mail]